Replies to post #49387 on $heff's $tation of $tocks & $olid DD

[$heff]

AIS..$2.32 The company looks good for an approval for Anturol into their PDUFA date. The challenge for me is trading it around the Phase III data for Libigel. That is why I won't be trading BPAX. There is significant upside or downside based on those results for BPAX. There is a huge short position of 19m shares which if about 17% of the O/S.

With AIS, I would feel more comfortable trading the PDUFA decision of Dec 8th knowing that the clinical trial information would follow. If the Libigel data were negative, it would drop the AIS share price to below $2 IMO. The closer the data release gets to the Anturol PDUFA date the less chance it has to run on a Positive PDUFA if the clinical trial info is not positive. Still determining what I am going to do with AIS as far as establishing a position before their PDUFA.